Quidel to Present Virtually at the Canaccord Genuity 40th Annual Growth Conference
July 29 2020 - 4:10PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced today that it will present
at the Canaccord Genuity 40th Annual Growth Conference, to be held
virtually on Wednesday, August 13, 2020.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present that day at 10:30
a.m. Eastern time (7:30 a.m. Pacific time) with a question and
answer session scheduled immediately following the presentation.
During the presentation, the company will discuss business and
financial developments and trends. The company's statements may
contain or constitute material information that has not been
previously disclosed.
A live webcast and audio archive of each presentation will be
available via the Investor Relations section of the company’s Web
site at http://ir.quidel.com or by clicking on the following
link:
http://wsw.com/webcast/canaccord42/qdel/
Participants should allow approximately five to ten minutes
prior to the presentation's start time to visit the site and
download any streaming media software needed to listen to the
Internet webcast. A replay of the webcast will also be available on
the company’s Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and
InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, COVID-19, influenza,
respiratory syncytial virus, Strep A, lyme, herpes, pregnancy,
thyroid disease and fecal occult blood. Quidel's Triage® system of
tests comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC),
offering a diverse immunoassay menu in a variety of tests to
provide diagnostic answers for quantitative BNP, CK-MB, d-dimer,
myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s
research and development engine is also developing a continuum of
diagnostic solutions from advanced immunoassay to molecular
diagnostic tests to further improve the quality of healthcare in
physicians’ offices and hospital and reference laboratories. For
more information about Quidel’s comprehensive product portfolio and
to explore exciting employment opportunities, visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200729005845/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931
Media and Investors Contact: Quidel Corporation Ruben Argueta
(858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Sep 2023 to Sep 2024